Callaghan B.C., Reynolds E., Banerjee M., Kerber K.A., Skolarus L.E., Magliocco B., Esper G.E., Burke J.F. (2019) Out-of-pocket costs are on the rise for commonly prescribed neurologic medications. Neurology. 2019; 92 (22)

Compston, A & Coles, A. (2008). Multiple sclerosis. Lancet. 372(9648), 1502-17.

Culpepper, W. J., Marrie, R. A., Langer-Gould, A., Wallin, M. T., Campbell, J. D., Nelson, L. M., et al. (2019). Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 92 (10). (open access)

Duquette P, Yeung M, Mouallif S, Nakhaipour HR, Haddad P, Schecter R (2019) A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies. PLoS ONE 14(1)

Hartung D., Bourdette D., Ahmed S., Whitham R. (2015). The cost of multiple sclerosis drugs in the US and the pharmaceutical industry; Too big to fail? Neurology. 2015; 84 (21)

healthline. 4 Possible Causes of Multiple Sclerosis (MS). Retrieved 11/9/2019.

Lee J., McPherson D., D’Ambrosi M., Stutsky, M. (2019). Correlates and barriers to medication adherence in multiple sclerosis patients and their impact on clinical outcomes. Journal of Drug Assessment. Vol. 8, 2019

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., … Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, 83(3), 278–286.

Lunde HMB,  Assmus J, Myhr K, Bø L, Grytten N. (2017). Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.  J Neurol Neurosurg Psychiatry. 2017 ;88(8):621-625.

National Institute of Neurological Disorders and Stroke (NINDS 2019). Multiple Sclerosis Information Page. Retrieved 10/31/2019.

National Multiple Sclerosis Society (NMSS) Retrieved 11/9/2019

National Multiple Sclerosis Society (2010). Nursing Home Care of Individuals with Multiple Sclerosis. Guidelines and Recommendations for Quality Care.

Nickerson M., Marrie R.A. (2013)  The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. BMC Neurol. 2013; 13: 119.

Palmer A.J., van der Mei I., Taylor B.V., Clarke P.M., Simpson S. Jr., Ahmad H. (2019) Multiple Sclerosis Journal. First Published February 26, 2019

Popescu, B. F., Pirko, I., & Lucchinetti, C. F. (2013). Pathology of multiple sclerosis: where do we stand?. Continuum (Minneapolis, Minn.), 19(4 Multiple Sclerosis), 901–921

Thompson AJ, Banwell BL, Barkhof F, et al. (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173

U.S. National Library of Medicine. Genetics Home Reference (GHR 2019) Multiple Sclerosis: Inheritance Pattern. 
Retrieved 11/1/2019.

Wallin M T., Culpepper W.J., Campbell J.D., Nelson L.M., Langer-Gould A., Marrie R.A., Cutter G. R., Kaye W.E., Wagner L., Tremlett H., Buka S.L., Dilokthornsakul P., Topol B., Chen L.H., LaRocca, N.G. (2019) The prevalence of MS in the United States. Neurology Mar 2019, 92 (10).

Wingerchuk, D.M. (2011). Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med. 78(2), 221-30.

Zurawski J., Glanz B., Chua A., Lokhande H., Rotstein D., Weiner H., Engler D., Chitnis T., Healy B.C .(2019) Time between expanded disability status scale (EDSS) scores. Multiple Sclerosis and Related Disorders. 30:98-103